



Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Cancer Therapy

Guest Editors:

Dr. Mao-Chih Hsieh

1. Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan
2. Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

Dr. Hsin-Hsien Yu

1. Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan
2. Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11696, Taiwan

Deadline for manuscript submissions:

closed (15 March 2024)

Message from the Guest Editors

Dear Colleagues,


Cancer with peritoneal metastasis is a special form of metastasis and is difficult to treat, though many new drugs have been applied. For the past few decades, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have provided another treatment option. Many patients do not experience recurrence after CRS/HIPEC. However, it seems that CRS/HIPEC is only effective for some types of cancer and there exist conflicts regarding treatment results. Furthermore, there is still no global consensus regarding timing, temperature setting, hyperthermic duration or even drug choice. Genetic alteration may be a factor affecting the treatment results. Minimal invasive CRS/HIPEC is currently in development. Many trials are ongoing, with possible new findings on the horizon. This Special Issue welcomes reviews, original research articles of clinical works, new techniques, diagnostic tools, clinical trials and experimental studies.

Dr. Mao-Chih Hsieh

Dr. Hsin-Hsien Yu

Guest Editors





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI